Meany Holly J
Center for Cancer and Blood Disorders, Children's National Health System, The George Washington University School of Medicine and Health Sciences, Washington, DC 20010, USA.
Children (Basel). 2019 Jan 8;6(1):5. doi: 10.3390/children6010005.
Neuroblastoma, a tumor of the sympathetic nervous system, is the most common extra-cranial neoplasm of childhood. Variables with prognostic significance in patients with neuroblastoma, including age at diagnosis, disease stage, tumor histology, gene amplification, tumor cell ploidy, and the presence of segmental chromosomal aberrations are utilized to classify patients based on risk of disease recurrence. Patients with non-high-risk neuroblastoma, low- and intermediate-risk categories, represent nearly half of all newly diagnosed cases. This group has an excellent event-free and overall survival with current therapy. Over time, the objective in treatment of non-high-risk neuroblastoma has been reduction of therapy intensity to minimize short- and long-term adverse events all the while maintaining excellent outcomes.
神经母细胞瘤是一种交感神经系统肿瘤，是儿童期最常见的颅外肿瘤。在神经母细胞瘤患者中具有预后意义的变量，包括诊断时的年龄、疾病分期、肿瘤组织学、基因扩增、肿瘤细胞倍性以及节段性染色体畸变的存在，被用于根据疾病复发风险对患者进行分类。非高危神经母细胞瘤患者，即低危和中危类别，占所有新诊断病例的近一半。这组患者采用当前治疗方法具有良好的无事件生存率和总生存率。随着时间的推移，非高危神经母细胞瘤的治疗目标一直是降低治疗强度，以尽量减少短期和长期不良事件，同时保持良好的治疗效果。
